Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2001

View Archived Issues

Aventis updates 2000 achievements and highlights emerging pipeline products

Introgen and Texas Heart Institute to study gene therapy for cardiovascular indications

Epix and InSightec begin alliance for development of antitumor treatment

Structured treatment interruptions with Remune in HIV-infected patients

ACC news: novel calcium channel antagonist shows potential in atrial fibrillation

Pathways involved in myocardial protective effect of new NHE inhibitor examined in pigs

Picovir shows efficacy for VRI treatment in pivotal studies

Novo Nordisk reports product pipeline progress

Na+/Ca2+ inhibition associated with both neuroprotective and cardioprotective effects

Cardiovascular effects of long-term treatment with AGE crosslink breaker in SHR

Mechanism of beneficial effects of spironolactone in CHF patients under investigation

Amgen's ARANESP recommended for approval by CPMP

Prophylactic mucosal vaccine against RSV effective and safe in mice

Tricyclic immunosuppressive and antiallergic compounds developed at Shionogi

New agents for HCV infection patented by DuPont scientists

Merck describes synthesis and use of new inhibitors of Ras prenylation

Potent and selective vesamicol receptor ligands from Daiichi Radioisotope and use in diagnosis

Boehringer Ingelheim identifies new succinate cathepsin inhibitors

Banyu presents new series of biarylurea CDK inhibitors as antineoplastic agents

AnorMED begins new phase I study of AMD-3100 at University of Washington

International patent covers new Pharmacia oxazolidinones

Bronchodilating effects reported for BM-531 at this week's AAAAI meeting

Arrow Therapeutics' novel antibiotic enters full development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.